Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz

Executive Summary

But agency had to weigh how presentation differences between Sandoz’s Zarxio and Amgen’s Neupogen, as well as Neupogen-specific safety information, should be reflected in the biosimilar’s labeling.

Advertisement

Related Content

FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Behind The Approval Letter: Drug Review Profiles
Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability
Sorry, Wrong Email: FDA’s ‘Oops’ Moment In The Zarxio Review
Zarxio Reviewers
FDA’s Inaugural Biosimilar Review Bumpier Than First Appeared
Zarxio Clinical Development Timeline
Sandoz’s Biosimilar Data-Bridging Plans For Zarxio Faced FDA Doubts
Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
Biosimilar But Different: Zarxio, Neupogen Diverge On Syringes, Vials

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel